Search
Immunocore Holdings PLC
IMCRAdd to Watchlist
28.600USD
+0.050+0.18%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
1.45BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Immunocore Holdings PLC is 8.12, ranking 53 out of 157 in the Pharmaceuticals industry. The average price target is 70.00, with a high of 100.00 and a low of 36.00.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
66.400
Target Price
+132.57%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Immunocore Holdings PLC
IMCR
17
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Immunocore Holdings PLC's expected revenue for the next quarter?
Immunocore Holdings PLC's expected revenue is 110.34M.
What is Immunocore Holdings PLC's price target?
Analysts forecast that Immunocore Holdings PLC's price target is USD 70.00, with the highest forecast at USD 100.00 and the lowest forecast at USD 36.00.
How have Immunocore Holdings PLCIMCR's recent earnings per share performed?
The market expectation was USD 0.26, while Immunocore Holdings PLCIMCR's earnings per share (EPS) for the previous quarter was USD -0.59. EPS for the next quarter is expected at USD 0.01.
What is the analyst rating for Immunocore Holdings PLC?
Based on the ratings of Immunocore Holdings PLC's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
